| Tamiko Robin Katsumoto, MD | |
|
300 Pasteur Dr, Stanford, CA 94305-2200 | |
| (650) 723-4000 | |
| Not Available |
| Full Name | Tamiko Robin Katsumoto |
|---|---|
| Gender | Female |
| Speciality | Rheumatology |
| Experience | 22 Years |
| Location | 300 Pasteur Dr, Stanford, California |
| Accepts Medicare Assignments | Yes. She accepts the Medicare-approved amount; you will not be billed for any more than the Medicare deductible and coinsurance. |
| Identifier | Type | State | Issuer |
|---|---|---|---|
| 1952571317 | NPI | - | NPPES |
| Taxonomy | Type | License (State) | Status |
|---|---|---|---|
| 207R00000X | Internal Medicine | A87253 (California) | Secondary |
| 207RR0500X | Internal Medicine - Rheumatology | A87253 (California) | Primary |
| Facility Name | Location | Facility Type |
|---|---|---|
| Stanford Health Care | Stanford, CA | Hospital |
| Group Practice Name | Group PECOS PAC ID | No. of Members |
|---|---|---|
| Stanford Health Care | 6709797491 | 2572 |
News Archive
Catalyst Health Solutions, Inc., announced today that it was named to the 2010 Fortune 100 Fastest-Growing Companies List. Catalyst has achieved this recognition for three consecutive years and four times in six years. The Company was also named on Fortune's Fastest-Growing All-Stars List.
Seattle Genetics, Inc. and Millennium: The Takeda Oncology Company, a wholly owned subsidiary of Takeda Pharmaceutical Company Limited, today announced that they have completed enrollment of a phase II clinical trial of brentuximab vedotin (SGN-35) for relapsed or refractory systemic anaplastic large cell lymphoma.
For patients with end-stage lung cancer, noninvasive ventilation (NIV) may be more effective at reducing breathing difficulty than standard oxygen therapy, and has the added advantage of reducing patients' reliance on morphine, thus improving lucidity in their final days, according to research presented at the American Thoracic Society's 2008 International Conference in Toronto on Tuesday, May 20.
Cook Medical has completed patient enrollment in a study evaluating a technique for achieving vascular access via below-the-knee arteries. The new access technique could be used in treating peripheral arterial disease, including patients with critical limb ischemia.
The U.S. Food and Drug Administration today approved TOBI Podhaler (tobramycin inhalation powder) for the management of cystic fibrosis patients with Pseudomonas aeruginosa, a bacterium that causes lung infections.
› Verified 5 days ago
| Entity Name | University Of California Sfgh Medical Group |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1154396208 PECOS PAC ID: 5496668410 Enrollment ID: O20031113000632 |
News Archive
Catalyst Health Solutions, Inc., announced today that it was named to the 2010 Fortune 100 Fastest-Growing Companies List. Catalyst has achieved this recognition for three consecutive years and four times in six years. The Company was also named on Fortune's Fastest-Growing All-Stars List.
Seattle Genetics, Inc. and Millennium: The Takeda Oncology Company, a wholly owned subsidiary of Takeda Pharmaceutical Company Limited, today announced that they have completed enrollment of a phase II clinical trial of brentuximab vedotin (SGN-35) for relapsed or refractory systemic anaplastic large cell lymphoma.
For patients with end-stage lung cancer, noninvasive ventilation (NIV) may be more effective at reducing breathing difficulty than standard oxygen therapy, and has the added advantage of reducing patients' reliance on morphine, thus improving lucidity in their final days, according to research presented at the American Thoracic Society's 2008 International Conference in Toronto on Tuesday, May 20.
Cook Medical has completed patient enrollment in a study evaluating a technique for achieving vascular access via below-the-knee arteries. The new access technique could be used in treating peripheral arterial disease, including patients with critical limb ischemia.
The U.S. Food and Drug Administration today approved TOBI Podhaler (tobramycin inhalation powder) for the management of cystic fibrosis patients with Pseudomonas aeruginosa, a bacterium that causes lung infections.
› Verified 5 days ago
| Entity Name | Stanford Health Care |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1437292927 PECOS PAC ID: 6709797491 Enrollment ID: O20031124000348 |
News Archive
Catalyst Health Solutions, Inc., announced today that it was named to the 2010 Fortune 100 Fastest-Growing Companies List. Catalyst has achieved this recognition for three consecutive years and four times in six years. The Company was also named on Fortune's Fastest-Growing All-Stars List.
Seattle Genetics, Inc. and Millennium: The Takeda Oncology Company, a wholly owned subsidiary of Takeda Pharmaceutical Company Limited, today announced that they have completed enrollment of a phase II clinical trial of brentuximab vedotin (SGN-35) for relapsed or refractory systemic anaplastic large cell lymphoma.
For patients with end-stage lung cancer, noninvasive ventilation (NIV) may be more effective at reducing breathing difficulty than standard oxygen therapy, and has the added advantage of reducing patients' reliance on morphine, thus improving lucidity in their final days, according to research presented at the American Thoracic Society's 2008 International Conference in Toronto on Tuesday, May 20.
Cook Medical has completed patient enrollment in a study evaluating a technique for achieving vascular access via below-the-knee arteries. The new access technique could be used in treating peripheral arterial disease, including patients with critical limb ischemia.
The U.S. Food and Drug Administration today approved TOBI Podhaler (tobramycin inhalation powder) for the management of cystic fibrosis patients with Pseudomonas aeruginosa, a bacterium that causes lung infections.
› Verified 5 days ago
| Entity Name | County Of Santa Clara |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1699885079 PECOS PAC ID: 1254244973 Enrollment ID: O20040113000784 |
News Archive
Catalyst Health Solutions, Inc., announced today that it was named to the 2010 Fortune 100 Fastest-Growing Companies List. Catalyst has achieved this recognition for three consecutive years and four times in six years. The Company was also named on Fortune's Fastest-Growing All-Stars List.
Seattle Genetics, Inc. and Millennium: The Takeda Oncology Company, a wholly owned subsidiary of Takeda Pharmaceutical Company Limited, today announced that they have completed enrollment of a phase II clinical trial of brentuximab vedotin (SGN-35) for relapsed or refractory systemic anaplastic large cell lymphoma.
For patients with end-stage lung cancer, noninvasive ventilation (NIV) may be more effective at reducing breathing difficulty than standard oxygen therapy, and has the added advantage of reducing patients' reliance on morphine, thus improving lucidity in their final days, according to research presented at the American Thoracic Society's 2008 International Conference in Toronto on Tuesday, May 20.
Cook Medical has completed patient enrollment in a study evaluating a technique for achieving vascular access via below-the-knee arteries. The new access technique could be used in treating peripheral arterial disease, including patients with critical limb ischemia.
The U.S. Food and Drug Administration today approved TOBI Podhaler (tobramycin inhalation powder) for the management of cystic fibrosis patients with Pseudomonas aeruginosa, a bacterium that causes lung infections.
› Verified 5 days ago
| Entity Name | Lpch Medical Group Div Of Lucile |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1417907940 PECOS PAC ID: 0840298543 Enrollment ID: O20061113000232 |
News Archive
Catalyst Health Solutions, Inc., announced today that it was named to the 2010 Fortune 100 Fastest-Growing Companies List. Catalyst has achieved this recognition for three consecutive years and four times in six years. The Company was also named on Fortune's Fastest-Growing All-Stars List.
Seattle Genetics, Inc. and Millennium: The Takeda Oncology Company, a wholly owned subsidiary of Takeda Pharmaceutical Company Limited, today announced that they have completed enrollment of a phase II clinical trial of brentuximab vedotin (SGN-35) for relapsed or refractory systemic anaplastic large cell lymphoma.
For patients with end-stage lung cancer, noninvasive ventilation (NIV) may be more effective at reducing breathing difficulty than standard oxygen therapy, and has the added advantage of reducing patients' reliance on morphine, thus improving lucidity in their final days, according to research presented at the American Thoracic Society's 2008 International Conference in Toronto on Tuesday, May 20.
Cook Medical has completed patient enrollment in a study evaluating a technique for achieving vascular access via below-the-knee arteries. The new access technique could be used in treating peripheral arterial disease, including patients with critical limb ischemia.
The U.S. Food and Drug Administration today approved TOBI Podhaler (tobramycin inhalation powder) for the management of cystic fibrosis patients with Pseudomonas aeruginosa, a bacterium that causes lung infections.
› Verified 5 days ago
| Mailing Address | Practice Location Address |
|---|---|
| Tamiko Robin Katsumoto, MD 300 Pasteur Dr, Stanford, CA 94305-2200 Ph: (650) 723-4000 | Tamiko Robin Katsumoto, MD 300 Pasteur Dr, Stanford, CA 94305-2200 Ph: (650) 723-4000 |
News Archive
Catalyst Health Solutions, Inc., announced today that it was named to the 2010 Fortune 100 Fastest-Growing Companies List. Catalyst has achieved this recognition for three consecutive years and four times in six years. The Company was also named on Fortune's Fastest-Growing All-Stars List.
Seattle Genetics, Inc. and Millennium: The Takeda Oncology Company, a wholly owned subsidiary of Takeda Pharmaceutical Company Limited, today announced that they have completed enrollment of a phase II clinical trial of brentuximab vedotin (SGN-35) for relapsed or refractory systemic anaplastic large cell lymphoma.
For patients with end-stage lung cancer, noninvasive ventilation (NIV) may be more effective at reducing breathing difficulty than standard oxygen therapy, and has the added advantage of reducing patients' reliance on morphine, thus improving lucidity in their final days, according to research presented at the American Thoracic Society's 2008 International Conference in Toronto on Tuesday, May 20.
Cook Medical has completed patient enrollment in a study evaluating a technique for achieving vascular access via below-the-knee arteries. The new access technique could be used in treating peripheral arterial disease, including patients with critical limb ischemia.
The U.S. Food and Drug Administration today approved TOBI Podhaler (tobramycin inhalation powder) for the management of cystic fibrosis patients with Pseudomonas aeruginosa, a bacterium that causes lung infections.
› Verified 5 days ago
Prista Charuworn, MD Rheumatology Medicare: Not Enrolled in Medicare Practice Location: 300 Pasteur Dr, Alway Build M211, Mc 5187, Stanford, CA 94305 Phone: 650-723-6661 | |
Yu Kuang Lai, MD Rheumatology Medicare: Accepting Medicare Assignments Practice Location: 300 Pasteur Dr, Stanford, CA 94305 Phone: 650-723-4000 | |
Andrea Lorenze, M.D. Rheumatology Medicare: Accepting Medicare Assignments Practice Location: 300 Pasteur Drive, Lane 154, Stanford, CA 94305 Phone: 650-723-6661 Fax: 650-498-6205 | |
Audra Horomanski, MD Rheumatology Medicare: Accepting Medicare Assignments Practice Location: 300 Pasteur Dr, Stanford, CA 94305 Phone: 650-723-4000 Fax: 650-498-6205 | |
Meghan Brady Marmor, MD Rheumatology Medicare: Accepting Medicare Assignments Practice Location: 300 Pasteur Dr, Stanford, CA 94305 Phone: 650-723-4000 | |
Lauren Michelle Ulsh, MD Rheumatology Medicare: Medicare Enrolled Practice Location: 300 Pasteur Dr, Stanford, CA 94305 Phone: 650-723-4000 | |
Ann M Chen, MD Rheumatology Medicare: Accepting Medicare Assignments Practice Location: 300 Pasteur Dr, A149, Mc5202, Stanford, CA 94305 Phone: 650-725-3376 Fax: 650-723-8305 |